The true face of the revolution in oncology drug development: A personal reflection

Current Clinical Pharmacology

Volumn 2, Issue 1, 2007, Pages 31-35

  Burgess, Michael ^a   de Alwis, Dinesh P ^b  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Biomarkers; Cytotoxics; Oncology; Pharmacodynamics; Pharmacokinetics; Targeted agents

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DAUNORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLIC ACID; GEFITINIB; GLYCOPROTEIN P; IMATINIB; METHOTREXATE; QUINIDINE; TARIQUIDAR; VALSPODAR; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG COMPETITION; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; HUMAN; LONG TERM CARE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 34248137632     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488407779422258     Document Type: Review

References (8)

1. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukaemia. Identification of a relation between concentration and effect. N Engl J Med 1986; 314: 471-477.
2. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002; 86: 1297-1302.
3. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-4721.
4. Stoll BR, Migliorini C, Kadambi A, Munn LL, Jain RK. A mathematical model for the contribution of endothelial progenitor cells to angiogenesis in tumours: implications for anti-angiogenic therapy. Blood 2003; 102: 2555-2561.
5. Simeoni M, Magni P Cammia C, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumour growth kinetics in xenograft models after administration of anti-cancer agents. Cancer Res 2004; 64: 1094-1011.
6. Dantzig AH, de Alwis DP, Burgess M. Considerations in the design and development of transport inhibitor as adjuncts to drug therapy. Advanced Drug Delivery Rev 2003; 55:133-55
7. Callies S, de Alwis DP, Mehta A, Burgess M and Aarons L. A Population Pharmacokinetic Model for Daunorubicin and Daunorubicinol Co-administered with Zosuquidar Trihydrochloride (LY335979). Cancer Chemother Pharmacol 2004; 53(6): 49-56.
8. Callies S, de Alwis DP, Wright JG, Sandler A, Burgess, M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel mdr modulator, Zosuquidar Trihydrochloride (LY335979). Cancer Chemother Pharmacol 2003; 51(2): 107-118.